Gandhi, Amit K.
Kim, Walter M.
Sun, Zhen-Yu J.
Huang, Yu-Hwa
Bonsor, Daniel A.
Sundberg, Eric J.
Kondo, Yasuyuki
Wagner, Gerhard
Kuchroo, Vijay K.
Petsko, Gregory
Blumberg, Richard S.
Article History
Received: 24 July 2018
Accepted: 5 November 2018
First Online: 30 November 2018
Competing Interests
: R.S.B. and V.K.K. are consultants to Syntalogic Phamaceuticals and R.S.B. has an equity interest in Syntalogic Phamaceuticals, which is developing therapeutics to target CEACAM1.